A Multicenter, Open Label, Active Control, Parallel-Group Randomized Study to Demonstrate Non Inferiority of Brinzolamide 1% Ophthalmic Suspension compared With Dorzox (Dorzolamide) 2% Ophthalmic Solution in Treatment of Elevated Intra-Ocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension

This is a multicenter, open label, active control, parallel-group randomized study to compare the reduction of elevated intra-ocular pressure (IOP) in patients with primary open angle glaucoma or ocular hypertension. 200 patients with primary open angle glaucoma or ocular hypertension will be randomized to receive either the test or the comparator drug, instilled in the eye three times daily for a period of 12 weeks. The primary outcome measure is to demonstrate IOP reduction from baseline and demonstrate non inferiority of brinzolamide (test) 1% ophthalmic suspension compared with Dorzox (dorzolamide - comparator) 2% ophthalmic solution.